Cholestech Corporation Announces the Appointment of Dr. Thomas E. Worthy as Vice President.HAYWARD, Calif.--(BW HealthWire)--Aug. 10, 1999-- Cholestech Corporation (Nasdaq:CTEC CTEC Course and Teacher Evaluation Council (Northwestern University, Office of the Register) CTEC Certified Technical Education Center CTEC Certified Technical Education Center (Microsoft) ) today announced the appointment of Dr. Thomas E. Worthy as Vice President, Development & Regulatory Affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: Dr. Worthy has been Cholestech's Director of Technical Affairs since April, 1998. Prior to joining Cholestech, Dr. Worthy was Director of Research and Development, Clinical Applications for Microgenics Corporation, a division of Boehringer Mannheim Corporation. Boehringer Mannheim Corporation is currently known as Roche Diagnostics Roche Diagnostics Division is a subsidiary of Hoffmann-La Roche which manufactures equipment and reagents for research and medical diagnostic applications. Internally, it is organized into six major business areas: Roche Applied Science, Roche Centralized Diagnostics, Roche . During his time with Microgenics, Dr. Worthy was responsible for clinical applications for the CEDIA CEDIA Custom Electronics Design and Installation Association CEDIA Cloned Enzyme Donor Immunoassay CEDIA Century Diamond product line. Prior to joining Microgenics, Dr. Worthy was Director of Research and Development for MetPath Inc., where he was responsible for the evaluation and development of new tests and instrumentation. Dr. Worthy holds a Ph.D. in Radiation Biology Radiation biology The study of the action of ionizing and nonionizing radiation on biological systems. Ionizing radiation includes highly energetic electromagnetic radiation (x-rays, gamma rays, or cosmic rays) and particulate radiation (alpha particles, beta from the University of Tennessee The University of Tennessee (UT), sometimes called the University of Tennessee at Knoxville (UT Knoxville or UTK), is the flagship institution of the statewide land-grant University of Tennessee public university system in the American state of Tennessee. . Commenting on Doctor Worthy's appointment, Warren E. Pinckert II, Cholestech's president and chief executive officer said, "During Tom's short time with Cholestech he has proven to be a valuable member of our management team. His excellent development experience and strong track record in the diagnostics industry will add strength to our efforts to continue to bring new products to market." The Cholestech L.D.X is a telephone-sized device that can conduct multiple simultaneous diagnostic tests from a single drop of blood and provide results, in less than five minutes, that are as accurate as similar tests performed in clinical and hospital labs. Cholestech Corporation manufactures and markets their proprietary system to healthcare, wellness, and disease management professionals for use in preventative care testing. The Cholestech L.D.X(R) System is positioned to benefit from the increasing emphasis on preventive health care and disease management. Cholestech's portfolio of CLIA-waived products is designed to offer efficient and economic diagnostic screening and therapeutic monitoring options that will ultimately enable people to lead longer, healthier, and more active lives. Cholestech Corporation has included in this press release certain "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 concerning Cholestech's business, operations and financial condition. The words or phrases "continue", "can be", "expects", "may affect", "may depend", "believes", "estimate", "project", and similar words and phrases Words and Phrases® A multivolume set of law books published by West Group containing thousands of judicial definitions of words and phrases, arranged alphabetically, from 1658 to the present. are intended to identify such forward-looking statements, including statements regarding Dr. Worthy's ability to add strength to our efforts to continue to bring new products to market, and the timing or impact of any newly developed products. Such forward-looking statements are subject to various known and unknown risks and uncertainties and Cholestech cautions you that any forward-looking information provided by or on behalf of Cholestech is not a guarantee of future performance. Actual results could differ materially from those anticipated in such forward-looking statements due to a number of factors, some of which are beyond Cholestech's control, in addition to those discussed in Cholestech's other press releases, public filings and statements by Cholestech's management, including (i) the competitive nature of the health care industry, (ii) changes in domestic and foreign economic and market conditions, (iii) the effect of federal, state and foreign regulation on Cholestech's business, (iv) failure of Cholestech, its vendors or other third parties to achieve Year 2000 compliance, and (v) the effect of any future new products or product acquisitions. All such forward-looking statements, are current only as of the date on which such statements were made. Actual results may be affected by additional factors set forth in the Company's Securities and Exchange Commission filings including Cholestech's most recently filed Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and Form 10-Q Form 10-Q See 10-Q. . Note to Editors: Cholestech L.D.X(R) System is a registered trademark of Cholestech Corporation. For more information about Cholestech, please visit our website at www.cholestech.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion